JP2016512488A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512488A5 JP2016512488A5 JP2015557554A JP2015557554A JP2016512488A5 JP 2016512488 A5 JP2016512488 A5 JP 2016512488A5 JP 2015557554 A JP2015557554 A JP 2015557554A JP 2015557554 A JP2015557554 A JP 2015557554A JP 2016512488 A5 JP2016512488 A5 JP 2016512488A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- oxo
- tetrahydrobenzo
- carboxamide
- oxazepin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 chloro, methyl Chemical group 0.000 claims description 348
- 150000003839 salts Chemical class 0.000 claims description 42
- 150000001875 compounds Chemical class 0.000 claims description 38
- LKYNGTHMKCTTQC-UHFFFAOYSA-N 1,2-oxazole-3-carboxamide Chemical compound NC(=O)C=1C=CON=1 LKYNGTHMKCTTQC-UHFFFAOYSA-N 0.000 claims description 31
- 125000001153 fluoro group Chemical group F* 0.000 claims description 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000001246 bromo group Chemical group Br* 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- LGYKLAMAEJSKNV-UHFFFAOYSA-N 5-benzyl-1,2-oxazole-3-carboxamide Chemical compound O1N=C(C(=O)N)C=C1CC1=CC=CC=C1 LGYKLAMAEJSKNV-UHFFFAOYSA-N 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 125000002971 oxazolyl group Chemical group 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims description 4
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 4
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims description 4
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000006304 2-iodophenyl group Chemical group [H]C1=C([H])C(I)=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 4
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 3
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims description 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 3
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims description 3
- 239000005973 Carvone Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 37
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 14
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 12
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 8
- 230000006378 damage Effects 0.000 claims 8
- 150000003857 carboxamides Chemical class 0.000 claims 7
- 230000007812 deficiency Effects 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 208000037816 tissue injury Diseases 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 4
- 230000001363 autoimmune Effects 0.000 claims 4
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000006872 improvement Effects 0.000 claims 4
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 claims 4
- 125000001425 triazolyl group Chemical group 0.000 claims 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- 125000006529 (C3-C6) alkyl group Chemical group 0.000 claims 3
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 125000003302 alkenyloxy group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- TVFIYRKPCACCNL-UHFFFAOYSA-N furan-2-carboxamide Chemical compound NC(=O)C1=CC=CO1 TVFIYRKPCACCNL-UHFFFAOYSA-N 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 230000000302 ischemic effect Effects 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- VOFNECDJUWZSFW-UHFFFAOYSA-N oxazepine-7-carboxamide Chemical compound NC(=O)C1=CC=CC=NO1 VOFNECDJUWZSFW-UHFFFAOYSA-N 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- PQQRHWFRZHFGFM-UHFFFAOYSA-N 1,3-thiazole-4-carboxamide Chemical compound NC(=O)C1=CSC=N1 PQQRHWFRZHFGFM-UHFFFAOYSA-N 0.000 claims 2
- 125000006507 2,4-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(F)C(=C1[H])C([H])([H])* 0.000 claims 2
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 claims 2
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 108010053317 Hexosaminidase A Proteins 0.000 claims 2
- 102000016871 Hexosaminidase A Human genes 0.000 claims 2
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 101710090077 NF-kappa-B essential modulator Proteins 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 102100027716 RanBP-type and C3HC4-type zinc finger-containing protein 1 Human genes 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 210000005013 brain tissue Anatomy 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000024557 hepatobiliary disease Diseases 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000005228 liver tissue Anatomy 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000003589 nefrotoxic effect Effects 0.000 claims 2
- 231100000381 nephrotoxic Toxicity 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 229960005489 paracetamol Drugs 0.000 claims 2
- 210000004738 parenchymal cell Anatomy 0.000 claims 2
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- LCDCPQHFCOBUEF-UHFFFAOYSA-N pyrrolidine-1-carboxamide Chemical compound NC(=O)N1CCCC1 LCDCPQHFCOBUEF-UHFFFAOYSA-N 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- SJCDBQHCQSIZHN-UHFFFAOYSA-N 1,2-dihydrotriazole-3-carboxamide Chemical compound NC(=O)N1NNC=C1 SJCDBQHCQSIZHN-UHFFFAOYSA-N 0.000 claims 1
- DSIBSRXKQRYPJP-UHFFFAOYSA-N 1,2-oxazole-5-carboxamide Chemical compound NC(=O)C1=CC=NO1 DSIBSRXKQRYPJP-UHFFFAOYSA-N 0.000 claims 1
- VAELWSLNTRVXQS-UHFFFAOYSA-N 1,3-oxazole-4-carboxamide Chemical compound NC(=O)C1=COC=N1 VAELWSLNTRVXQS-UHFFFAOYSA-N 0.000 claims 1
- OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical compound CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 claims 1
- JHAHAUYJIIKYIC-UHFFFAOYSA-N 1-methylpyrazole-4-carboxamide Chemical compound CN1C=C(C(N)=O)C=N1 JHAHAUYJIIKYIC-UHFFFAOYSA-N 0.000 claims 1
- 125000006481 2-iodobenzyl group Chemical group [H]C1=C([H])C(I)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 claims 1
- 125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 claims 1
- RPAQJGKCTXWKJI-GGYWPGCISA-N 3-benzyl-n-[(3s)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]piperidine-1-carboxamide Chemical compound N([C@H]1COC2=CC=CC=C2N(C1=O)C)C(=O)N(C1)CCCC1CC1=CC=CC=C1 RPAQJGKCTXWKJI-GGYWPGCISA-N 0.000 claims 1
- 125000006279 3-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Br)=C1[H])C([H])([H])* 0.000 claims 1
- BPXCLLWXDHBFRH-UHFFFAOYSA-N 3-methoxypropanamide Chemical compound COCCC(N)=O BPXCLLWXDHBFRH-UHFFFAOYSA-N 0.000 claims 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 1
- KNOUWGGQMADIBV-KRWDZBQOSA-N 5-benzyl-n-[(3s)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,2-oxazole-3-carboxamide Chemical compound N([C@H]1COC2=CC=CC=C2N(C1=O)C)C(=O)C(=NO1)C=C1CC1=CC=CC=C1 KNOUWGGQMADIBV-KRWDZBQOSA-N 0.000 claims 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 1
- 208000029602 Alpha-N-acetylgalactosaminidase deficiency Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 108090000426 Caspase-1 Proteins 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010011777 Cystinosis Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 208000028568 Free sialic acid storage disease Diseases 0.000 claims 1
- 201000008892 GM1 Gangliosidosis Diseases 0.000 claims 1
- 208000001905 GM2 Gangliosidoses Diseases 0.000 claims 1
- 201000008905 GM2 gangliosidosis Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 206010019851 Hepatotoxicity Diseases 0.000 claims 1
- 101001045440 Homo sapiens Beta-hexosaminidase subunit alpha Proteins 0.000 claims 1
- 101001081220 Homo sapiens RanBP-type and C3HC4-type zinc finger-containing protein 1 Proteins 0.000 claims 1
- 208000028226 Krabbe disease Diseases 0.000 claims 1
- 208000003221 Lysosomal acid lipase deficiency Diseases 0.000 claims 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims 1
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims 1
- 208000008955 Mucolipidoses Diseases 0.000 claims 1
- 206010072927 Mucolipidosis type I Diseases 0.000 claims 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
- 208000000149 Multiple Sulfatase Deficiency Disease Diseases 0.000 claims 1
- 208000035032 Multiple sulfatase deficiency Diseases 0.000 claims 1
- 102100022219 NF-kappa-B essential modulator Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims 1
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 101710164093 RanBP-type and C3HC4-type zinc finger-containing protein 1 Proteins 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 208000013608 Salla disease Diseases 0.000 claims 1
- 208000021811 Sandhoff disease Diseases 0.000 claims 1
- 208000000828 Sialic Acid Storage Disease Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 108700001567 Type I Schindler Disease Proteins 0.000 claims 1
- 108090000848 Ubiquitin Proteins 0.000 claims 1
- 102000044159 Ubiquitin Human genes 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 125000005336 allyloxy group Chemical group 0.000 claims 1
- 201000008333 alpha-mannosidosis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- CRQQGFGUEAVUIL-UHFFFAOYSA-N chlorothalonil Chemical compound ClC1=C(Cl)C(C#N)=C(Cl)C(C#N)=C1Cl CRQQGFGUEAVUIL-UHFFFAOYSA-N 0.000 claims 1
- 208000024042 cholesterol ester storage disease Diseases 0.000 claims 1
- 208000013760 cholesteryl ester storage disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 238000010586 diagram Methods 0.000 claims 1
- 201000008049 fucosidosis Diseases 0.000 claims 1
- 201000004502 glycogen storage disease II Diseases 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 210000005003 heart tissue Anatomy 0.000 claims 1
- 231100000304 hepatotoxicity Toxicity 0.000 claims 1
- 230000007686 hepatotoxicity Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000007769 mucolipidosis Diseases 0.000 claims 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
- IIZWFTNGDCXXNB-IBGZPJMESA-N n-[(3s)-7-acetamido-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5-benzyl-1,2-oxazole-3-carboxamide Chemical compound N([C@H]1COC2=CC=C(NC(C)=O)C=C2N(C1=O)C)C(=O)C(=NO1)C=C1CC1=CC=CC=C1 IIZWFTNGDCXXNB-IBGZPJMESA-N 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
- 230000004264 retinal detachment Effects 0.000 claims 1
- 208000013223 septicemia Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- QFQXPBASSDNECX-UHFFFAOYSA-N 3-amino-1-methyl-7-(2,2,2-trifluoro-1,1-dihydroxyethyl)-4,5-dihydro-3h-1-benzazepin-2-one Chemical compound C1CC(N)C(=O)N(C)C2=CC=C(C(O)(O)C(F)(F)F)C=C21 QFQXPBASSDNECX-UHFFFAOYSA-N 0.000 description 1
- 0 CC=C(C=C(C(*)*C[C@]1NCOC=CC=CF)N(C)C1=O)C(O)=O Chemical compound CC=C(C=C(C(*)*C[C@]1NCOC=CC=CF)N(C)C1=O)C(O)=O 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361765664P | 2013-02-15 | 2013-02-15 | |
| US61/765,664 | 2013-02-15 | ||
| US201361790044P | 2013-03-15 | 2013-03-15 | |
| US61/790,044 | 2013-03-15 | ||
| PCT/IB2014/059004 WO2014125444A1 (en) | 2013-02-15 | 2014-02-14 | Heterocyclic amides as kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018044611A Division JP6352571B1 (ja) | 2013-02-15 | 2018-03-12 | キナーゼ阻害剤としての複素環式アミド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512488A JP2016512488A (ja) | 2016-04-28 |
| JP2016512488A5 true JP2016512488A5 (enExample) | 2017-03-23 |
| JP6321045B2 JP6321045B2 (ja) | 2018-05-09 |
Family
ID=50151350
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015557554A Active JP6321045B2 (ja) | 2013-02-15 | 2014-02-14 | キナーゼ阻害剤としての複素環式アミド |
| JP2018044611A Active JP6352571B1 (ja) | 2013-02-15 | 2018-03-12 | キナーゼ阻害剤としての複素環式アミド |
| JP2018107215A Pending JP2018150372A (ja) | 2013-02-15 | 2018-06-04 | キナーゼ阻害剤としての複素環式アミド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018044611A Active JP6352571B1 (ja) | 2013-02-15 | 2018-03-12 | キナーゼ阻害剤としての複素環式アミド |
| JP2018107215A Pending JP2018150372A (ja) | 2013-02-15 | 2018-06-04 | キナーゼ阻害剤としての複素環式アミド |
Country Status (37)
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI637951B (zh) | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
| EP3182974A1 (en) | 2014-08-21 | 2017-06-28 | GlaxoSmithKline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
| WO2016075239A1 (en) * | 2014-11-14 | 2016-05-19 | Boehringer Ingelheim International Gmbh | Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (sstr4) agonists |
| MX2017007607A (es) | 2014-12-11 | 2018-05-28 | Harvard College | Inhibidores de necrosis celular y metodos relacionados. |
| CN107207485A (zh) * | 2015-02-13 | 2017-09-26 | 葛兰素史密斯克莱知识产权发展有限公司 | (S)‑5‑苄基‑N‑(5‑甲基‑4‑氧代‑2,3,4,5‑四氢苯并[b][1,4]氧氮杂环庚三烯‑3‑基)‑4H‑1,2,4‑三唑‑3‑甲酰胺的晶型 |
| WO2016139181A1 (en) | 2015-03-02 | 2016-09-09 | Apeiron Biologics Ag | Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases |
| TWI730959B (zh) * | 2015-05-19 | 2021-06-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| CA2990564A1 (en) * | 2015-06-22 | 2016-12-29 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic heterocyclic amide derivative |
| MX380753B (es) * | 2015-07-02 | 2025-04-01 | Hoffmann La Roche | Lactamas bicíclicas y métodos de uso de las mismas. |
| CN108200760B (zh) | 2015-07-22 | 2022-04-01 | 英安塔制药有限公司 | 作为rsv抑制剂的苯并二氮杂䓬衍生物 |
| JP6754772B2 (ja) * | 2015-10-23 | 2020-09-16 | 武田薬品工業株式会社 | 複素環化合物 |
| US10709692B2 (en) | 2015-12-04 | 2020-07-14 | Denali Therapeutics Inc. | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| EP3402799B1 (en) | 2016-01-15 | 2022-05-04 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
| EA201891620A1 (ru) * | 2016-02-05 | 2019-02-28 | Денали Терапьютикс Инк. | Ингибиторы взаимодействующей с рецептором протеинкиназы 1 |
| US10898469B2 (en) | 2016-02-26 | 2021-01-26 | Sumitomo Dainippon Pharma Co., Ltd. | Imidazolylamide derivative |
| WO2018007973A2 (en) | 2016-07-06 | 2018-01-11 | Glaxosmithkline Intellectual Property Development Limited | Process and intermediates for preparing benzoxazepines |
| JP7349359B2 (ja) * | 2016-10-17 | 2023-09-22 | エフ． ホフマン－ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| TW201831464A (zh) | 2016-11-18 | 2018-09-01 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| AR110282A1 (es) * | 2016-12-02 | 2019-03-13 | Hoffmann La Roche | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 |
| PL3552017T3 (pl) | 2016-12-09 | 2022-08-08 | Denali Therapeutics Inc. | Związki użyteczne jako inhibitory RIPK1 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| WO2018117196A1 (ja) | 2016-12-20 | 2018-06-28 | 大日本住友製薬株式会社 | がん幹細胞を標的とする医薬 |
| WO2018129287A1 (en) | 2017-01-06 | 2018-07-12 | Enanta Pharmaceuticals, Inc. | Heteroaryldiazepine derivatives as rsv inhibitors |
| EP3582784B1 (en) | 2017-02-16 | 2022-06-08 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of benzodiazepine derivatives |
| JP2020509009A (ja) * | 2017-02-27 | 2020-03-26 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | キナーゼ阻害剤としての複素環式アミド |
| JOP20190233A1 (ar) * | 2017-04-14 | 2019-10-02 | Biogen Ma Inc | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون |
| EP3612223B1 (en) * | 2017-04-17 | 2024-07-31 | National Institute Of Biological Sciences, Beijing | Treating male senescence |
| WO2018213632A1 (en) * | 2017-05-17 | 2018-11-22 | Denali Therapeutics Inc. | Kinase inhibitors and uses thereof |
| US10752598B2 (en) | 2017-06-07 | 2020-08-25 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as RSV inhibitors |
| WO2019006291A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| WO2019006295A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| AR112274A1 (es) | 2017-07-14 | 2019-10-09 | Hoffmann La Roche | Compuestos bicíclicos de cetona y sus métodos de uso |
| AU2018339068B2 (en) | 2017-09-29 | 2022-12-15 | Enanta Pharmaceuticals, Inc. | Combination pharmaceutical agents as RSV inhibitors |
| AU2018348930A1 (en) | 2017-10-11 | 2020-03-26 | F. Hoffmann-La Roche Ag | Bicyclic compounds for use as RIP 1 kinase inhibitors |
| MX2020003451A (es) | 2017-10-31 | 2020-08-03 | Hoffmann La Roche | Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos. |
| MX394621B (es) | 2017-11-13 | 2025-03-24 | Enanta Pharm Inc | Procesos para la resolucion de los derivados de la benzodiazepina-2-ona y de la benzoazepin-2-ona |
| US10647711B2 (en) | 2017-11-13 | 2020-05-12 | Enanta Pharmaceuticals, Inc. | Azepin-2-one derivatives as RSV inhibitors |
| WO2019123219A1 (en) | 2017-12-20 | 2019-06-27 | Glaxosmithkline Intellectual Property Development Limited | Crystalline salt form of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide |
| CN111741957A (zh) | 2017-12-29 | 2020-10-02 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为激酶抑制剂的杂环酰胺 |
| WO2019199908A1 (en) | 2018-04-11 | 2019-10-17 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
| EP3781571B1 (en) | 2018-04-20 | 2024-01-17 | F. Hoffmann-La Roche AG | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| CN110407770B (zh) * | 2018-04-27 | 2022-12-30 | 复旦大学 | 3-取代-1,5-苯并氮杂䓬类化合物及其药物用途 |
| EA202092580A1 (ru) | 2018-05-03 | 2021-04-07 | Ригел Фармасьютикалз, Инк. | Соединения, ингибирующие rip1, а также способы их получения и применения |
| WO2019213445A1 (en) | 2018-05-03 | 2019-11-07 | Rigel Pharmaceuticals, Inc. | Rip1 inhibitory compounds and methods for making and using the same |
| WO2019224774A1 (en) | 2018-05-23 | 2019-11-28 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors |
| WO2019224773A1 (en) | 2018-05-23 | 2019-11-28 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors |
| WO2020001420A1 (zh) * | 2018-06-26 | 2020-01-02 | 中国科学院上海有机化学研究所 | 一类细胞坏死抑制剂及其制备方法和用途 |
| CN110642874B (zh) * | 2018-06-26 | 2023-03-28 | 中国科学院上海有机化学研究所 | 一类细胞坏死抑制剂及其制备方法和用途 |
| LT3594199T (lt) * | 2018-07-09 | 2020-11-10 | F.I.S.- Fabbrica Italiana Sintetici S.P.A. | Kristalinis 2-fluor-3-nitroluenas ir jo paruošimo būdas |
| WO2020044206A1 (en) | 2018-08-29 | 2020-03-05 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors for use in the treatment cancer |
| CN109134448B (zh) * | 2018-10-16 | 2020-11-27 | 中南大学湘雅医院 | 杂环化合物及其盐、制备方法、用途和药物 |
| CN111138448B (zh) * | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| JP7045526B2 (ja) | 2018-11-02 | 2022-03-31 | 中国科学院上海薬物研究所 | Ｒｉｐ１キナーゼを阻害する複素環状アミド及びその使用 |
| SG11202105007TA (en) | 2018-11-21 | 2021-06-29 | Enanta Pharm Inc | Functionalized heterocycles as antiviral agents |
| TW202043229A (zh) | 2019-01-11 | 2020-12-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環酮化合物及其使用方法 |
| KR102769633B1 (ko) * | 2019-01-25 | 2025-02-19 | 베이징 사이텍-엠큐 파마슈티컬즈 리미티드 | 아실아미노 가교된 헤테로사이클릭 화합물, 및 이의 조성물 및 응용 |
| PH12021552201A1 (en) | 2019-03-18 | 2022-05-30 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| US11179400B2 (en) | 2019-04-09 | 2021-11-23 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| BR112021023040A2 (pt) | 2019-05-17 | 2021-12-28 | Glaxosmithkline Ip Dev Ltd | Composição de matriz compreendendo (s)-5-benzil-n-(5- metil-4-oxo-2,3,4,5-tetrahidrobenzo[b][1,4]oxazepin-3-il)-4h-1,2,4- triazol-3-carboxamida |
| CA3142360C (en) | 2019-05-31 | 2023-11-14 | Medshine Discovery Inc. | Bicyclic compound as rip-1 kinase inhibitor and application thereof |
| US12365695B2 (en) * | 2019-08-09 | 2025-07-22 | Bisichem Co., Ltd. | Fused ring heteroaryl compounds as RIPK1 inhibitors |
| WO2021043966A1 (en) * | 2019-09-06 | 2021-03-11 | Inflazome Limited | Nlrp3 inhibitors |
| MX2022002718A (es) | 2019-09-06 | 2022-08-10 | Rigel Pharmaceuticals Inc | Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos. |
| CN114728958B (zh) | 2019-09-06 | 2025-05-02 | 里格尔药品股份有限公司 | Rip1抑制性化合物和制备与使用其的方法 |
| WO2021046515A1 (en) | 2019-09-06 | 2021-03-11 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| IL291665B2 (en) | 2019-09-27 | 2025-07-01 | Univ Texas | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| MX2022003984A (es) | 2019-10-04 | 2022-07-27 | Enanta Pharm Inc | Compuestos heterociclicos antivirales. |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| KR20250095767A (ko) * | 2019-11-07 | 2025-06-26 | 리겔 파마슈티칼스, 인크. | 헤테로시클릭 rip1 억제 화합물 |
| WO2021108198A1 (en) * | 2019-11-26 | 2021-06-03 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| MX2022010693A (es) * | 2020-02-28 | 2022-09-26 | Univ Texas | Compuestos, composiciones y metodos para inhibidores de la proteina quinasa que interactua con el receptor i para el tratamiento de enfermedades. |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TW202214617A (zh) | 2020-06-02 | 2022-04-16 | 法商賽諾菲公司 | 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途 |
| TWI824259B (zh) | 2020-07-01 | 2023-12-01 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| US11534439B2 (en) | 2020-07-07 | 2022-12-27 | Enanta Pharmaceuticals, Inc. | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors |
| BR112023002660A2 (pt) * | 2020-08-18 | 2023-03-14 | Hutchison Medipharma Ltd | Compostos de pirimidinona e usos dos mesmos |
| US11945824B2 (en) | 2020-10-19 | 2024-04-02 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| CN114716427B (zh) * | 2021-01-07 | 2024-04-26 | 成都贝诺科成生物科技有限公司 | 一种作为rip抑制剂的化合物及其制备方法和用途 |
| WO2022171110A1 (en) * | 2021-02-10 | 2022-08-18 | Zai Lab (Us) Llc | Fused tricyclic compounds as rip1-kinase inhibitors and uses thereof |
| WO2022171111A1 (en) * | 2021-02-10 | 2022-08-18 | Zai Lab (Us) Llc | Heteroaryl-fused bicyclic compound as rip1-kinase inhibitors and uses thereof |
| AR125587A1 (es) * | 2021-03-11 | 2023-08-02 | Rigel Pharmaceuticals Inc | Inhibidores heterocíclicos de la quinasa de rip1 |
| CN113045560B (zh) * | 2021-03-30 | 2022-09-06 | 港科鹏禾生物(苏州)有限公司 | 一种酰胺类衍生物及其制备方法和应用 |
| CA3214802A1 (en) | 2021-04-02 | 2022-10-06 | Genentech, Inc. | Processes for making bicyclic ketone compounds |
| US20240228506A1 (en) * | 2021-04-27 | 2024-07-11 | Merck Sharp & Dohme Llc | Ripk1 inhibitors and methods of use |
| CN115246796A (zh) * | 2021-04-27 | 2022-10-28 | 中国科学院上海有机化学研究所 | 一种抑制细胞程序性死亡的化合物及其制备方法 |
| AU2022328136A1 (en) | 2021-08-10 | 2023-11-30 | Abbvie Inc. | Nicotinamide ripk1 inhibitors |
| CN119528915A (zh) * | 2021-09-14 | 2025-02-28 | 中国科学院上海有机化学研究所 | 抑制细胞程序性死亡的化合物及其制备方法 |
| AU2022346718A1 (en) * | 2021-09-17 | 2024-03-28 | Bisichem Co., Ltd. | Fused heterocyclic rings as ripk1 inhibitors |
| US20250019373A1 (en) * | 2021-10-22 | 2025-01-16 | Voronoi Inc. | Aryl or heteroaryl derivative, and pharmaceutical composition comprising same as active ingredient for prevention or treatment of kinase-related diseases |
| CN113876778B (zh) * | 2021-11-05 | 2023-04-14 | 中日友好医院(中日友好临床医学研究所) | Kw2449在制备改善类风湿性关节炎药物中的应用 |
| TW202340182A (zh) | 2021-11-11 | 2023-10-16 | 美商健臻公司 | 做為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途 |
| WO2023119210A1 (ko) * | 2021-12-24 | 2023-06-29 | 제일약품주식회사 | Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| MX2024008648A (es) | 2022-01-12 | 2024-09-23 | Denali Therapeutics Inc | Formas cristalinas de (s)-5-bencil-n-(5-metil-4-oxo-2,3,4,5-tetrah idropirido [3,2- b][1,4]oxacepin-3-il)-4h-1,2,4-triazol-3-carboxam ida. |
| WO2023174374A1 (zh) | 2022-03-16 | 2023-09-21 | 江苏恒瑞医药股份有限公司 | 稠杂环类化合物、其制备方法及其在医药上的应用 |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| US12162857B2 (en) | 2022-04-27 | 2024-12-10 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
| CN114736197B (zh) * | 2022-06-13 | 2022-09-13 | 南京医工医药技术有限公司 | 咪唑啉酮衍生物及其用途 |
| WO2023240379A1 (zh) * | 2022-06-13 | 2023-12-21 | 南京医工医药技术有限公司 | 咪唑啉酮衍生物及其用途 |
| CN117447460A (zh) * | 2022-07-13 | 2024-01-26 | 南京天印健华医药科技有限公司 | 作为ripk1抑制剂的杂环化合物 |
| CN119731170A (zh) | 2022-08-19 | 2025-03-28 | 建新公司 | 作为ripk1抑制剂的异噁唑烷及其使用 |
| TW202423921A (zh) * | 2022-08-22 | 2024-06-16 | 美商安塔製藥公司 | 稠合的雜雙環抗病毒劑 |
| CN117645579A (zh) * | 2022-09-02 | 2024-03-05 | 科辉智药生物科技(深圳)有限公司 | 作为ripk1抑制剂的氮杂䓬类稠环化合物及其应用 |
| WO2024158665A1 (en) * | 2023-01-23 | 2024-08-02 | Genzyme Corporation | Drug formulations of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2h-pyrido [3,4-f] [1,4] oxazepine-9-c arbonitrile |
| CN121079291A (zh) | 2023-05-10 | 2025-12-05 | 建新公司 | 作为ripk1抑制剂的异噁唑烷及其使用 |
| WO2024233547A1 (en) | 2023-05-10 | 2024-11-14 | Genzyme Corporation | Isoxazolidines as ripk1 inhibitors and use thereof |
| CN121127467A (zh) | 2023-05-10 | 2025-12-12 | 建新公司 | 作为ripk1抑制剂的异噁唑烷及其用途 |
| US20250000872A1 (en) * | 2023-06-26 | 2025-01-02 | Eli Lilly And Company | Formulations and dosing regimens for rip1 kinase inhibitors for treating autoimmune and inflammatory diseases |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5239065B2 (enExample) | 1971-11-17 | 1977-10-03 | ||
| EP0166357A3 (en) * | 1984-06-26 | 1988-10-26 | Merck & Co. Inc. | Benzofused lactams and pharmaceutical compositions containing them |
| US4692522A (en) | 1985-04-01 | 1987-09-08 | Merck & Co., Inc. | Benzofused lactams useful as cholecystokinin antagonists |
| US5206234A (en) | 1990-10-22 | 1993-04-27 | Merck & Co., Inc. | Benzolactam analogs as antagonists of cck |
| JP3358069B2 (ja) * | 1991-12-24 | 2002-12-16 | 武田薬品工業株式会社 | 三環性複素環類、その製造法及び剤 |
| ATE235472T1 (de) | 1995-06-07 | 2003-04-15 | Merck & Co Inc | N-(2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepi - 3-yl)-3-amide |
| WO1998041510A1 (en) | 1997-03-14 | 1998-09-24 | Shionogi & Co., Ltd. | Novel benzolactam derivatives and medicinal compositions comprising the same |
| US6228854B1 (en) | 1997-08-11 | 2001-05-08 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
| FR2781483A1 (fr) * | 1998-07-21 | 2000-01-28 | Hoechst Marion Roussel Inc | Derives de thioazepinone, procede de preparation et intermediaires de ce procede, application a titre de medicament et compositions pharmaceutiques les renfermant |
| EP1226139A2 (en) | 1999-07-06 | 2002-07-31 | Vertex Pharmaceuticals Incorporated | Cyclized amide derivatives for treating or preventing neuronal damage |
| MXPA02005070A (es) | 1999-11-18 | 2003-09-25 | Antexpharma Inc | 1-benzazepinas sustituidas y derivados de las mismas. |
| JP2003535046A (ja) | 2000-04-03 | 2003-11-25 | デュポン ファーマシューティカルズ カンパニー | Ａβタンパク質産生の阻害剤としての環状ラクタム |
| BR0110051A (pt) | 2000-04-03 | 2004-12-07 | Bristol Myers Squibb Pharma Co | Composto, uso do composto, composição farmacêutica e método de tratamento do mal de alzheimer |
| WO2001092235A1 (en) | 2000-06-01 | 2001-12-06 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
| DE10054279A1 (de) | 2000-11-02 | 2002-05-16 | Apotech Res & Dev Ltd | Verwendung von Liganden von Todesrezeptoren oder RIP zur Auslösung des Caspase-unabhängigen Zelltods und Verbindungen zur Inhibition des Caspase-unabhängigen Zelltods |
| CA2447687A1 (en) | 2001-05-16 | 2002-12-19 | Antexpharma, Inc. | Substituted 1-benzazepines and derivatives thereof |
| US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| EP1620567A1 (en) | 2003-04-15 | 2006-02-01 | Hans-Jürgen Thiesen | Method for diagnosing rheumatoid arthritis or osteoarthritis |
| DE602004016992D1 (de) * | 2003-05-02 | 2008-11-20 | Elan Pharm Inc | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3-carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen |
| WO2005028664A2 (en) | 2003-09-17 | 2005-03-31 | University Of Massachusetts | Modulation of programmed necrosis |
| EP1640012A1 (de) | 2004-09-24 | 2006-03-29 | Salama, Zoser B. nat.rer.Dr. | Pharmazeutisches Mittel enthaltend Blutbestandteile 10 kDa und deren Verwendung zur Prophylaxe und Behandlung von Defekten des Immunsystems |
| US20060067942A1 (en) | 2004-09-24 | 2006-03-30 | Salama Zoser B | Pharmaceutical agent comprising amino acids, peptides, proteins and/or fractions and fragments thereof and the use of same in the prophylaxis and treatment of immune system deficiency in humans and animals |
| FR2894968B1 (fr) | 2005-12-20 | 2008-02-22 | Trophos Sa | Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation |
| CA2633500A1 (en) * | 2005-12-20 | 2007-07-05 | President And Fellows Of Harvard College | Compounds, screens, and methods of treatment |
| FR2899108B1 (fr) | 2006-03-31 | 2012-02-03 | Trophos | Utilisation de derives du cholest-4-en-3-one pour l'obtention d'un medicament cytoprotecteur |
| US8007790B2 (en) | 2006-04-03 | 2011-08-30 | Stowers Institute For Medical Research | Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases |
| FR2907783A1 (fr) | 2006-10-30 | 2008-05-02 | Trophos Sa | Nouveaux composes chimiques, leurs procedes de synthese et leur utilisation a titre de medicament, particulierement a titre de medicament cytoprotecteur, neuroprotecteur ou cardioprotecteur |
| WO2008086043A2 (en) | 2007-01-10 | 2008-07-17 | Wyeth | Methods and compositions for assessment and treatment of asthma |
| CA2677331A1 (en) | 2007-02-28 | 2008-09-04 | Merck & Co., Inc. | Substituted benzodiazepinones, benzoxazepinones and benzothiazepinones as sodium channel blockers |
| JP5239065B2 (ja) | 2007-04-20 | 2013-07-17 | 株式会社大一商会 | 遊技機 |
| WO2009023272A1 (en) | 2007-08-15 | 2009-02-19 | President And Fellows Of Harvard College | Heterocyclic inhibitors of necroptosis |
| FR2934596B1 (fr) | 2008-07-30 | 2015-04-10 | Trophos | Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation |
| US8257921B1 (en) | 2008-12-22 | 2012-09-04 | Schering Corporation | NRIP1 regulation of apolipoprotein A1 |
| WO2010075290A1 (en) | 2008-12-22 | 2010-07-01 | President And Fellows Of Harvard College | Unsaturated heterocyclic inhibitors of necroptosis |
| US20120122889A1 (en) | 2008-12-23 | 2012-05-17 | President And Fellows Of Harvard College | Small molecule inhibitors of necroptosis |
| FR2940650B1 (fr) | 2008-12-29 | 2017-01-27 | Trophos | Nouveaux derives d'oxime du 3,5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant,et procede de preparation |
| US7622106B1 (en) | 2009-03-06 | 2009-11-24 | Board Of Regents, The University Of Texas System | Necrosis assay |
| KR101155506B1 (ko) | 2009-07-08 | 2012-06-15 | 고려대학교 산학협력단 | 활성산소조절 유전자를 이용한 ｔｎｆ-알파 유도 질병의 치료제 및 예방제의 스크리닝 방법 |
| WO2011080314A2 (en) | 2009-12-31 | 2011-07-07 | Deutsches Krebsforschungszentrum | Novel modulators of trail signalling |
| US20130005726A1 (en) | 2010-03-08 | 2013-01-03 | Derek Abbott | Compositions and methods for treating inflammatory disorders |
| WO2011133964A2 (en) | 2010-04-23 | 2011-10-27 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells |
| EP2593425B1 (en) | 2010-07-16 | 2018-10-17 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their method of use |
| US20120022116A1 (en) | 2010-07-20 | 2012-01-26 | Huayun Deng | Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex |
| US20140024598A1 (en) | 2010-11-01 | 2014-01-23 | Demetrios Vavvas | Methods and compositions for preserving retinal ganglion cells |
| WO2012125544A2 (en) | 2011-03-11 | 2012-09-20 | President And Fellows Of Harvard College | Necroptosis inhibitors and methods of use therefor |
| WO2013013826A1 (en) | 2011-07-27 | 2013-01-31 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Necroptosis inhibitors for the treatment of inflammatory diseases of the gastrointestinal tract |
| EP2758780A4 (en) | 2011-09-22 | 2015-09-16 | Marv Entpr Llc | METHOD OF TREATING MULTIPLE SCLEROSIS |
| CN102343102A (zh) | 2011-10-19 | 2012-02-08 | 柳忠辉 | 激活素受体相互作用蛋白2基因在制备药物中的应用 |
| US20140357570A1 (en) | 2011-10-21 | 2014-12-04 | Massachusetts Eye And Ear Infirmary | Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders |
| KR101410332B1 (ko) | 2012-02-29 | 2014-06-24 | 코아스템(주) | 중간엽 기질세포 배양용 항산화 조성물 및 이의 용도 |
| ES2446494B1 (es) | 2012-03-28 | 2015-03-16 | Consejo Superior De Investigaciones Científicas (Csic) | Aplicación terapéutica de necrostatina-1 en esteatohepatitis |
| WO2014022102A1 (en) | 2012-08-01 | 2014-02-06 | Amgen Inc. | Methods of using anti-apoptotic compounds to modulate one or more properties of a cell culture |
| ES2813407T3 (es) | 2012-08-06 | 2021-03-23 | Brainstorm Cell Therapeutics Ltd | Métodos para generar células madre mesenquimales que secretan factores neurotróficos |
| JP6449779B2 (ja) | 2012-12-26 | 2019-01-09 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 目的遺伝子発現の線形結合を用いた細胞信号伝達経路活性の評価 |
| JPWO2014126127A1 (ja) | 2013-02-13 | 2017-02-02 | 国立大学法人北海道大学 | ネクロプトーシス関連疾患の治療用医薬組成物及びその有効成分のスクリーニング方法 |
| TWI637951B (zh) * | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
| CN105593373A (zh) | 2013-02-27 | 2016-05-18 | 博德研究所 | T细胞平衡基因表达、物质组合物及其使用方法 |
| WO2014145022A1 (en) | 2013-03-15 | 2014-09-18 | President And Fellows Of Harvard College | Hybrid necroptosis inhibitors |
| EP3182974A1 (en) | 2014-08-21 | 2017-06-28 | GlaxoSmithKline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
| EA201891620A1 (ru) | 2016-02-05 | 2019-02-28 | Денали Терапьютикс Инк. | Ингибиторы взаимодействующей с рецептором протеинкиназы 1 |
-
2014
- 2014-02-13 TW TW103104666A patent/TWI637951B/zh active
- 2014-02-13 TW TW107104621A patent/TWI648274B/zh active
- 2014-02-13 TW TW107104622A patent/TWI638815B/zh active
- 2014-02-13 TW TW107104619A patent/TWI648273B/zh active
- 2014-02-14 TR TR2018/08112T patent/TR201808112T4/tr unknown
- 2014-02-14 MY MYPI2015702652A patent/MY178552A/en unknown
- 2014-02-14 LT LTEP18155836.2T patent/LT3342771T/lt unknown
- 2014-02-14 JP JP2015557554A patent/JP6321045B2/ja active Active
- 2014-02-14 SM SM20210083T patent/SMT202100083T1/it unknown
- 2014-02-14 MX MX2018008312A patent/MX373867B/es unknown
- 2014-02-14 US US14/763,183 patent/US9556152B2/en active Active
- 2014-02-14 ES ES18152185T patent/ES2814556T3/es active Active
- 2014-02-14 BR BR122017002946A patent/BR122017002946A2/pt not_active Application Discontinuation
- 2014-02-14 KR KR1020197004425A patent/KR102267977B1/ko active Active
- 2014-02-14 ES ES14705891.1T patent/ES2672530T3/es active Active
- 2014-02-14 BR BR122017002951A patent/BR122017002951A2/pt not_active Application Discontinuation
- 2014-02-14 MX MX2015010572A patent/MX360715B/es active IP Right Grant
- 2014-02-14 CR CR20190512A patent/CR20190512A/es unknown
- 2014-02-14 HR HRP20180900TT patent/HRP20180900T1/hr unknown
- 2014-02-14 BR BR122017002949A patent/BR122017002949A2/pt not_active Application Discontinuation
- 2014-02-14 DK DK14705891.1T patent/DK2956452T3/en active
- 2014-02-14 CN CN201810758606.XA patent/CN108774214B/zh active Active
- 2014-02-14 RS RS20180698A patent/RS57332B1/sr unknown
- 2014-02-14 SM SM20180289T patent/SMT201800289T1/it unknown
- 2014-02-14 RS RS20210156A patent/RS61439B1/sr unknown
- 2014-02-14 NZ NZ628447A patent/NZ628447A/en unknown
- 2014-02-14 EA EA201591506A patent/EA028991B1/ru not_active IP Right Cessation
- 2014-02-14 HU HUE14705891A patent/HUE037763T2/hu unknown
- 2014-02-14 SG SG11201505796TA patent/SG11201505796TA/en unknown
- 2014-02-14 EP EP14705891.1A patent/EP2956452B1/en active Active
- 2014-02-14 KR KR1020157024819A patent/KR102228764B1/ko active Active
- 2014-02-14 DK DK18155836.2T patent/DK3342771T3/da active
- 2014-02-14 EP EP19154374.3A patent/EP3508484B1/en active Active
- 2014-02-14 CR CR20190511A patent/CR20190511A/es unknown
- 2014-02-14 EP EP18152185.7A patent/EP3375780B1/en active Active
- 2014-02-14 MA MA44820A patent/MA44820B1/fr unknown
- 2014-02-14 WO PCT/IB2014/059004 patent/WO2014125444A1/en not_active Ceased
- 2014-02-14 EA EA201792039A patent/EA031971B1/ru not_active IP Right Cessation
- 2014-02-14 PT PT147058911T patent/PT2956452T/pt unknown
- 2014-02-14 CA CA2900695A patent/CA2900695C/en active Active
- 2014-02-14 SI SI201431772T patent/SI3342771T1/sl unknown
- 2014-02-14 MX MX2018008311A patent/MX373866B/es unknown
- 2014-02-14 PL PL14705891T patent/PL2956452T3/pl unknown
- 2014-02-14 PT PT181558362T patent/PT3342771T/pt unknown
- 2014-02-14 ES ES18155836T patent/ES2855135T3/es active Active
- 2014-02-14 BR BR112015019627-6A patent/BR112015019627B1/pt active IP Right Grant
- 2014-02-14 CN CN201480021120.8A patent/CN105121432B/zh active Active
- 2014-02-14 MY MYPI2020000331A patent/MY195183A/en unknown
- 2014-02-14 CN CN201710029656.XA patent/CN106928203B/zh active Active
- 2014-02-14 HU HUE18155836A patent/HUE053215T2/hu unknown
- 2014-02-14 UY UY0001035330A patent/UY35330A/es not_active Application Discontinuation
- 2014-02-14 UA UAA201508769A patent/UA118259C2/uk unknown
- 2014-02-14 PL PL18155836T patent/PL3342771T3/pl unknown
- 2014-02-14 EP EP18155836.2A patent/EP3342771B1/en active Active
- 2014-02-14 SI SI201430738T patent/SI2956452T1/en unknown
- 2014-02-14 PE PE2015001727A patent/PE20151752A1/es not_active Application Discontinuation
- 2014-02-14 LT LTEP14705891.1T patent/LT2956452T/lt unknown
- 2014-02-14 AU AU2014217453A patent/AU2014217453B2/en active Active
-
2015
- 2015-07-21 ZA ZA2015/05267A patent/ZA201505267B/en unknown
- 2015-07-28 PH PH12015501675A patent/PH12015501675A1/en unknown
- 2015-07-30 IL IL240280A patent/IL240280B/en active IP Right Grant
- 2015-08-14 CL CL2015002279A patent/CL2015002279A1/es unknown
- 2015-08-14 DO DO2015000196A patent/DOP2015000196A/es unknown
- 2015-08-14 CR CR20150420A patent/CR20150420A/es unknown
-
2016
- 2016-09-21 US US15/271,581 patent/US9624202B2/en active Active
-
2017
- 2017-03-15 US US15/459,141 patent/US10292987B2/en active Active
- 2017-12-08 US US15/835,747 patent/US20180098998A1/en not_active Abandoned
- 2017-12-22 IL IL256500A patent/IL256500B/en active IP Right Grant
- 2017-12-22 IL IL256502A patent/IL256502B/en active IP Right Grant
-
2018
- 2018-02-15 PH PH12018500342A patent/PH12018500342A1/en unknown
- 2018-02-15 PH PH12018500343A patent/PH12018500343A1/en unknown
- 2018-02-15 PH PH12018500341A patent/PH12018500341A1/en unknown
- 2018-03-12 JP JP2018044611A patent/JP6352571B1/ja active Active
- 2018-04-04 DO DO2018000088A patent/DOP2018000088A/es unknown
- 2018-04-04 DO DO2018000089A patent/DOP2018000089A/es unknown
- 2018-06-04 JP JP2018107215A patent/JP2018150372A/ja active Pending
- 2018-06-08 CY CY20181100604T patent/CY1120320T1/el unknown
-
2019
- 2019-03-12 US US16/299,254 patent/US10933070B2/en active Active
- 2019-05-10 US US16/408,718 patent/US10940154B2/en active Active
-
2021
- 2021-02-12 CY CY20211100121T patent/CY1123915T1/el unknown
- 2021-02-12 HR HRP20210252TT patent/HRP20210252T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512488A5 (enExample) | ||
| CA2849169C (en) | Pyrazole carboxamides as janus kinase inhibitors | |
| JP2012525349A5 (enExample) | ||
| JP2010513444A5 (enExample) | ||
| JP6017313B2 (ja) | 化合物および方法 | |
| CA2670605A1 (en) | Substituted arylpyrazoles | |
| JP2017524028A (ja) | 薬剤としてのｒｉｐ１キナーゼ阻害剤である複素環式アミド | |
| JP2017538750A5 (enExample) | ||
| RU2017125520A (ru) | Соединения, ингибирующие parg | |
| JP2010533158A5 (enExample) | ||
| RU2011116226A (ru) | Пиразолопиридиновые производные как ингибиторы надфн-оксидазы | |
| WO2002062804A1 (en) | Oxazolyl-pyrazole derivatives as kinase inhibitors | |
| JP2008525502A (ja) | 抗炎症薬 | |
| AU2002246076A1 (en) | Oxazolyl-pyrazole derivatives as kinase inhibitors | |
| JP2017512794A5 (enExample) | ||
| RU2019132212A (ru) | Селективные ингибиторы hdac6 | |
| JP2010504280A5 (enExample) | ||
| CA2521201A1 (en) | Substituted pyrazoles for use in the prophylaxis or treatment of a disease which can be influenced by the binding of the substitued pyrazoles to 5ht receptors | |
| CA2554686A1 (en) | Compounds | |
| RU2016102137A (ru) | Первичные карбоксамиды в качестве ингибиторов bik | |
| JP2014525444A5 (enExample) | ||
| RU2012143794A (ru) | Производные n-(имидазопиримидин-7-ил)-гетероаламидов и их применение в качестве ингибиторов pde10a | |
| KR20070007103A (ko) | 벤즈아미드 유도체 및 이의 글루코키나아제 활성화제로서의용도 | |
| ME02053B (me) | Oksazol supstituisani indazoli kao inhibitori pi3-kinaze | |
| JP2020516671A5 (enExample) |